NAD+ Levels by Age: How the Decline Unfolds, Decade by Decade

There is a molecule inside every cell of your body that quietly determines how well that cell makes energy, repairs its own DNA, and keeps its inflammation in check. It is called NAD+ (nicotinamide adenine dinucleotide), and you have measurably less of it at 50 than you did at 20. By the time most people reach midlife, direct measurements in human tissue suggest the level has fallen by roughly half. ¹

That single number explains a surprising amount of ordinary experience: the recovery from a hard day that takes a little longer than it used to, the afternoon energy dip that did not exist a decade ago, the sense that the body is running the same processes on a smaller budget. This article follows that decline across the decades, looks at why it accelerates rather than holding steady, and asks the more interesting question most pieces skip entirely: why does this happen at all? The honest answer, as we will see, is probably not what the longevity marketing suggests.

The fall in NAD+ with age is not a theoretical concern lifted from a textbook. It has been measured directly in human tissue. In a frequently cited study, Massudi and colleagues quantified NAD+ in human skin biopsies spanning a wide age range and found a clear, progressive decline across adult life, alongside rising markers of oxidative stress. ¹ The same broad pattern has since been described across multiple tissues and species in the wider literature. ² The headline figure people remember is the roughly 50% drop by the middle decades of life, and it is a reasonable summary of the direction and scale, even if the exact percentage varies by tissue and by the method used to measure it.

It helps to picture the trajectory rather than a single statistic. The table below is a narrative map, not a clinical chart: NAD+ is not routinely tested in your annual blood work, and individuals vary enormously. But the broad arc, and the way it tends to surface in everyday life, is consistent enough to be useful.

The reason this map is worth carrying in your head is that the decline is not the same shape for everyone, and it is not strictly linear. To understand why it tends to speed up rather than hold steady, we have to look at what is consuming NAD+, not just at what is producing it.

It is tempting to think of NAD+ decline as a slow leak: production simply tapers off and the level drifts down. That is only half the picture, and it is the less important half. The level of any molecule is set by the balance between how much is made and how much is consumed. With NAD+, the consumption side rises sharply with age, which is what turns a gentle slope into something steeper in later life.

The single biggest age-related NAD+ consumer is an enzyme called CD38. Its activity rises progressively as we get older, and as it rises it breaks down NAD+ faster than younger tissue ever did. ³ The trigger for that rise appears to be the low-grade, chronic inflammation that accumulates with age, often called inflammaging. CD38 is heavily expressed on immune cells, and the inflammatory signalling environment of older tissue drives its expression upward. ²

This is the crux of a problem that pure precursor supplementation runs into over time. If you only supply more raw material (more NMN) to a system where CD38 is increasingly active, a growing share of what you add is degraded before it can be used. The older the tissue, the more this matters. It is the central reason that addressing the breakdown side, not just the supply side, becomes more important with each decade, and the specific rationale for pairing a CD38 inhibitor with NMN in a formulation built for older users.

The second major consumer is a family of enzymes called PARP. Their job is genuinely useful: PARP enzymes detect and help repair DNA damage. The complication is that they pay for that repair in NAD+. Every repair event consumes it, and DNA damage accumulates as we age, so PARP activity rises with the damage load. When PARP becomes heavily activated in damaged or ageing cells, it can rapidly deplete the intracellular NAD+ pool. ⁴ So the body finds itself in a bind: the very repair work that ageing makes more necessary is also draining the molecule that the rest of the cell depends on.

Put CD38 and PARP together and the acceleration makes sense. Production is drifting down at the same time that two demand-side systems are ramping up, one driven by inflammation, the other by accumulating damage. The deficit compounds from both ends, which is why later decades feel different in kind, not just in degree, from the slow start in your 30s.

One of the easiest mistakes in this area is to treat NAD+ as a single body-wide number. It is not. NAD+ is made, used, and depleted locally, and different tissues sit on different timelines. ² This is why two people the same age can experience the decline so differently, and why no single symptom is the universal first sign.

Skeletal muscle is where the energy story is most familiar. Muscle relies on NAD+ to convert fuel into usable energy and to recover after exertion, and its NAD+-producing capacity falls with age, which contributes to the slower recovery and reduced stamina many people notice from their 40s onward. Encouragingly, muscle is also the tissue most responsive to physical activity, which can partly offset the local decline.

The brain has enormous and constant energy demands and limited capacity to rest a cell the way muscle can. Neurons depend on NAD+ for energy and for DNA repair, and falling NAD+ in the brain is one of the mechanisms researchers connect to age-related changes in cognition and mental stamina. This is the tissue behind the experience of slower processing or a shorter ceiling on concentration.

Immune cells are a special case because they both depend on NAD+ and consume large amounts of it, particularly through CD38. As the immune system shifts into the chronic low-grade activation of inflammaging, it draws down NAD+ precisely in the cells responsible for resilience against infection. This is part of why bouncing back from illness can feel harder with age.

The liver is a metabolic hub that uses NAD+ heavily for processing fats, sugars, and the by-products of everyday metabolism. Its NAD+ status is closely tied to how forgiving, or unforgiving, metabolism feels, which is part of the reason the same diet that once sat lightly can feel heavier in later decades.

The practical message is not to obsess over any one organ. It is that NAD+ decline is a whole-system phenomenon that shows up first wherever your own weakest link happens to be: energy for one person, recovery for another, mental sharpness or immune resilience for a third.

There is one more reason falling NAD+ matters so much, and it is worth keeping brief. A family of repair-and-maintenance enzymes called sirtuins, especially SIRT1 and SIRT3, are entirely dependent on NAD+. They are not just cofactors that borrow it; they consume it with every reaction they catalyse. ⁵ Sirtuins are part of how cells repair DNA, restrain inflammation, and keep their mitochondria efficient. As NAD+ falls, sirtuin activity falls with it, and a layer of cellular housekeeping quietly slows down.

This creates a compounding loop: less NAD+ means quieter sirtuins, which means maintenance falls behind, which leaves the cell less able to cope, on top of the energy shortfall from the decline itself. NAD+, sirtuins, and the consuming enzymes are all parts of one interconnected system. ⁶ If you want the full account of how sirtuins work and why pairing NAD+ support with a direct sirtuin activator makes sense, see our sirtuins article. For the purposes of this piece, the one-line version is enough: NAD+ is the currency the longevity enzymes spend, and they are increasingly short of it as the decades pass.

Because the decline is gradual and the starting point differs, the sensible reason to think about NAD+ is not the same at every age. Three rough milestones capture most readers.

The decline has begun but the gap is still small, and the consuming enzymes are not yet running hot. Most people in this group feel fine, which is exactly the point: the goal here is not to fix a deficit but to support a system before it has eroded. Foundational lifestyle inputs (regular movement, sleep, a varied diet) do most of the work at this stage, and a modest, single-ingredient NMN dose is a reasonable, low-key addition rather than a corrective. This is the profile The Base (250mg NMN as Uthever™) was designed for: a clean entry point, without the additional ingredients that a younger system does not yet particularly need.

By this decade the deficit is established, and the consumption side has shifted: CD38 activity is meaningfully higher, and PARP is busier as DNA damage accumulates. This is the group most likely to feel that "energy and recovery have quietly shifted." It is also the group for whom supplying precursor alone is least efficient, because more of what you add is being degraded by the very enzymes that have risen with age. That is the logic behind The Repair (450mg NMN plus ApiAge® apigenin 50mg as a CD38 inhibitor and trans-pterostilbene): it addresses supply and breakdown together, which matters more the further along the curve you are.

Here the baseline is low and consumption is high, so the priority shifts from optimisation to protection of the systems that carry resilience: energy, recovery, cognition, and immune function. The case for addressing the breakdown side, not just topping up supply, is strongest in this group, since CD38 activity is at its highest. The Repair's combined approach is aimed squarely at this profile. For those who prefer the NR pathway, The Plus (NR) is an alternative precursor, and the two precursors raise NAD+ by slightly different routes. ⁸

The honest framing matters here, because the supplement field is not short of overclaiming. NMN does not reverse ageing and it does not reset your NAD+ to a 25-year-old's level on a permanent basis. What the human evidence supports is more grounded: oral NMN raises blood NAD+, and in older adults that has been linked to measurable functional changes. In a placebo-controlled trial in older men, 250mg of NMN daily for 12 weeks elevated blood NAD+ and was associated with changes in some measures of muscle function, such as gait speed. ⁹ A separate randomised trial in amateur runners found NMN improved aerobic capacity. ¹⁰ These are real effects in real people, with sensible effect sizes rather than miracle ones.

The mechanistic reason supplementation is worth considering is the one this whole article has been building toward. The decline is driven substantially by rising consumption, not only by falling production. So the more complete approach in later decades is not just to add precursor, but to protect what you add. That is why The Repair combines NMN (to supply NAD+) with apigenin (to limit CD38-driven breakdown) and trans-pterostilbene (to support the sirtuins that NAD+ fuels). For a younger user whose CD38 is still relatively quiet, the simpler The Base covers the supply side without ingredients aimed at a problem that has not yet arrived.

NAD+ decline is one of the more clearly documented features of human ageing. It begins quietly in the 30s, becomes substantial by the 40s and 50s, and reaches a low baseline under high consumption pressure in the 60s and beyond. The decline accelerates rather than holding steady because two NAD+-consuming systems, CD38 and PARP, rise with age, the first driven by inflammation and the second by accumulating DNA damage. And it almost certainly is not a programmed clock: it is the metabolic cost of processes the body runs for other, sensible reasons.

That last point is the optimistic one. Because the decline is a side effect rather than a designed program, supporting NAD+, by supplying precursor and protecting it from accelerated breakdown, is a coherent thing to attempt rather than a fight against the body's own intentions. What is sensible to do about it shifts with the decade: stay ahead of the curve in your 30s, address an established gap in your 50s, protect resilience in your 60s. If the energy and recovery you have today feel different from what they were ten years ago, there is now a well-documented cellular story behind that feeling, and a clear, evidence-grounded place to start. We follow the evidence. When it changes, so will we.

For Youth is a science-led longevity brand focused on developing clinically relevant supplements that support healthy ageing and performance at the cellular level. Formulated in collaboration with leading academic researchers, the brand prioritises evidence-based ingredients, advanced delivery technologies, and transparent quality standards.